Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Bactroban Generics Petition Cites FDA Topical Bioequivalence Methods

Executive Summary

A citizen petition from GlaxoSmithKline seeking to block Bactroban Cream (mupirocin) generics revisits the question of whether generics of topical dermatologic drug products containing different forms of the active ingredient should be approved by FDA

You may also be interested in...

Topical Bioequivalence For Unlike Emulsions Should Be Tested In Vivo – FDA

Bioequivalence of topical dermatologic drugs in different emulsions that target the stratum corneum should be determined through in vivo testing, FDA said

Ranbaxy Generic Ceftin May Clear FDA After USP Monograph Revision

Ranbaxy expects an ANDA approval for its generic version of GlaxoSmithKline's Ceftin shortly after U.S. Pharmacopeia monograph revisions for cefuroxime axetil become effective on Sept. 30.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts